Why the ALKIVIA results matter for Zai Lab stock

Zai Lab (ZLAB) stock action is currently anchored to fresh clinical data from the ALKIVIA Phase 3 trial of VYVGART Hytrulo in autoimmune myositis, which met its primary endpoint with statistically significant results.

The study showed a 15.4 point greater improvement in Total Improvement Score at Week 52 versus placebo in the combined immune mediated necrotizing myopathy and dermatomyositis population, with benefits emerging by Week 4 and maintained through one year of treatment.

The ALKIVIA announcement has arrived during a strong upswing for Zai Lab, with a 30 day share price return of 44.04% and a 90 day share price return of 51.61%, even though the 1 year total shareholder return is still down 16.76%.

Surf 39 healthcare AI stocks to see which other healthcare stocks are quietly building positions in higher need areas alongside Zai Lab's autoimmune push.

The ALKIVIA win strengthens the case that Zai Lab has real assets in high-need autoimmune niches. After a 90 day share price gain above 50%, the key issue now is whether that business strength is already fully priced in.

Most Popular Narrative: 19.5% Undervalued

The most followed valuation narrative currently places Zai Lab's fair value at $33.30 versus the recent close at $26.82, which frames the current rally against a still sizeable gap.

Multiple high potential product launches and label expansions over the next 12 to 18 months, including VYVGART, bemarituzumab, KarXT, TIVDAK and Tumor Treating Fields, combined with a deep pipeline in oncology and immunology, are expected to significantly increase Zai Lab's addressable market and diversify revenue streams, supporting both top-line growth and future earnings.

Curious how that product rollout, expected revenue growth and future profit margins stack up to reach that fair value. The crux of this narrative is how far operating performance would need to shift from today's losses to support that pricing power. Want to see which assumptions around growth, profitability and valuation multiples hold the whole case together.

Result: Fair Value of $33.30 (UNDERVALUED)

However, Zai Lab still faces real pressure from heavy reliance on in licensed assets and ongoing losses, which could keep margins and any rerating below current narrative assumptions.

Next Steps

Given the mix of optimism around Zai Lab and concern about its risks, it makes sense to review the data yourself and move quickly while sentiment is live. A good place to start is by weighing the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Zai Lab?

If Zai Lab has your attention, do not stop here. Use fresh ideas from curated stock lists to pressure test your portfolio and spot gaps before others do.

• Target potential mispricings by reviewing companies flagged as 46 high quality undervalued stocks that may offer more attractive entry points.
• Strengthen your downside protection by scanning a 76 resilient stocks with low risk scores that focuses on resilience when conditions get tougher.
• Get ahead of the crowd by checking a 20 high quality undiscovered gems that highlights quality businesses still flying under most investors' radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.